5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 18 (1) , 58-63
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Fluoropyrimidine-induced cardiotoxicityCritical Reviews in Oncology/Hematology, 2018
- 5-fluorouracil and cardiotoxicity: a reviewTherapeutic Advances in Medical Oncology, 2018
- Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With ResectionAnnals of Surgery, 2017
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerAnnals of Oncology, 2014
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)Journal of Clinical Oncology, 2012
- 5-fluorouracil induced cardiotoxicity: Review of the literatureCardiology Journal, 2012
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal CancerJournal of Clinical Oncology, 2009
- Cardiotoxicity of 5-FluorouracilCardiovascular & Hematological Agents in Medicinal Chemistry, 2006
- Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracilAnnals of Oncology, 2002